Skip to main content

Citius Oncology, Inc.

corporate_fare Company Profile

Citius Oncology, Inc.

CTOR·NASDAQ·Life Sciences·CIK 0001851484

The Company, headquartered in Cranford, New Jersey, is a biopharmaceutical company that develops and sells specialized cancer treatments. Its main goal is to become a market leader by creating new therapies that have lower development and clinical risks, and strong competitive advantages through intellectual property and regulatory protection. This includes new versions of drugs already approved with significant safety and effectiveness data, or new uses for existing approved treatments. The Company's primary product is LYMPHIR TM, an engineered IL-2 diphtheria toxin fusion protein, used to treat patients with persistent or recurrent CTCL, a rare type of non-Hodgkin lymphoma. LYMPHIR received approval from the U.S. Food and Drug Administration (FDA) in August 2024 and was introduced to the market in December 2025. The Company plans to sell its products directly in the U.S. and collaborate with partners to market products outside the U.S. It has created a small, focused oncology sales team, initially for LYMPHIR, targeting major cancer centers in key regions. This approach is expected to generate direct sales revenue and royalty income. On August 23, 2021, Citius Pharma created Citius Acquisition Corp. ("SpinCo") as a wholly-owned subsidiary for the acquisition of LYMPHIR. SpinCo started operations in April 2022 when Citius Pharma transferred the LYMPHIR-related assets, including license agreements with Eisai Co., Ltd. and asset purchase agreements with Dr. Reddy's Laboratories SA.

Citius Oncology, Inc. (NASDAQ:CTOR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for CTOR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for CTOR spans 8-K, 424B3, 10-Q, SCHEDULE 13D/A.

Recent high-impact activity:

  • Citius Oncology: LYMPHIR Wholesaler Units Jump 120% in Fiscal Q4
  • Citius Oncology Wins Nasdaq Extension to April 19, 2027 to Reclaim $1.00 Bid
  • Citius Oncology Files Prospectus Supplement: Board Expansion, Q3 Losses, Going Concern Warning
  • Citius Oncology's Q3 Loss, Going Concern Warning, and Nasdaq Delisting Risk
  • Citius Oncology Q3 FY2026: $7.1M Revenue, 44 Institutions Ordering LYMPHIR

Financial Snapshot

Fiscal year ended September 30, 2025
Net Income
-$24.76M
Diluted EPS
-$0.34
Op. Cash Flow
-$5.49M
Operating Income
-$23.52M
Cash & Equivalents
$3.92M
Debt / Equity
0.00×
Shares Outstanding
83.51M sh
Source: 10-K · filed 2025-12-23 · accession 0001213900-25-125331

Short Interest & Short Volume

1.19 days to cover

FINRA reported short interest of 201,913 shares in CTOR as of the October 30, 2026 settlement, a 11.2% decrease from the prior period — about 1.2 days to cover at its recent average daily volume. On November 20, 2026, 22.5% of CTOR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)201,913 shares as of October 30, 2026
Change vs prior period▼ 11.2%
Days to cover1.19 at avg daily volume of 170,140
Daily short volume (FINRA facilities)22.5% of 28,601 shares on November 20, 2026
5-day average short volume45.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CTOR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-01.

1 recent capital raise1 shelf registration

Resale Registration Filed · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$0.5035
52-week range · as of 2026-10-26 $0.4912 – $1.93
Market cap
$46.82M
Volume
52.6K (0.4× avg)
3-mo avg 138.6K
Live data · 2026-11-22 12:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CTOR - Latest Insights

CTOR
Oct 26, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.588
Real-time Price: $0.5035 info
Change: -$0.0845 (-14%) info
Market Cap: $46.816M info
CTOR
Oct 23, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5795
Real-time Price: $0.5035 info
Change: -$0.076 (-13%) info
Market Cap: $46.816M info
CTOR
Aug 14, 2026, 5:22 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.8399
Real-time Price: $0.5035 info
Change: -$0.3364 (-40%) info
Market Cap: $46.816M info
CTOR
Aug 14, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.8862
Real-time Price: $0.5035 info
Change: -$0.3827 (-43%) info
Market Cap: $46.816M info
CTOR
Aug 14, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8862
Real-time Price: $0.5035 info
Change: -$0.3827 (-43%) info
Market Cap: $46.816M info
CTOR
Aug 05, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.658
Real-time Price: $0.5035 info
Change: -$0.1545 (-23%) info
Market Cap: $46.816M info
CTOR
Aug 05, 2026, 9:17 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $0.6346
Real-time Price: $0.5035 info
Change: -$0.1311 (-21%) info
Market Cap: $46.816M info
CTOR
Jun 04, 2026, 4:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.7959
Real-time Price: $0.5035 info
Change: -$0.2924 (-37%) info
Market Cap: $46.816M info
CTOR
Jun 01, 2026, 4:45 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.7923
Real-time Price: $0.5035 info
Change: -$0.2888 (-36%) info
Market Cap: $46.816M info
CTOR
Jun 01, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.7923
Real-time Price: $0.5035 info
Change: -$0.2888 (-36%) info
Market Cap: $46.816M info
CTOR
May 29, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.7634
Real-time Price: $0.5035 info
Change: -$0.2599 (-34%) info
Market Cap: $46.816M info
CTOR
May 22, 2026, 4:15 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.8399
Real-time Price: $0.5035 info
Change: -$0.3364 (-40%) info
Market Cap: $46.816M info
CTOR
May 19, 2026, 4:30 PM EDT
Filing Type: PRE 14C
Importance Score:
9
Price at Filing: $0.8282
Real-time Price: $0.5035 info
Change: -$0.3247 (-39%) info
Market Cap: $46.816M info
CTOR
May 15, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.930
Real-time Price: $0.5035 info
Change: -$0.4265 (-46%) info
Market Cap: $46.816M info
CTOR
May 15, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.930
Real-time Price: $0.5035 info
Change: -$0.4265 (-46%) info
Market Cap: $46.816M info
CTOR
May 15, 2026, 4:30 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $0.9633
Real-time Price: $0.5035 info
Change: -$0.4598 (-48%) info
Market Cap: $46.816M info
CTOR
May 06, 2026, 4:30 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.9093
Real-time Price: $0.5035 info
Change: -$0.4058 (-45%) info
Market Cap: $46.816M info
CTOR
May 06, 2026, 8:55 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9001
Real-time Price: $0.5035 info
Change: -$0.3966 (-44%) info
Market Cap: $46.816M info
CTOR
May 05, 2026, 8:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.9721
Real-time Price: $0.5035 info
Change: -$0.4686 (-48%) info
Market Cap: $46.816M info
CTOR
May 05, 2026, 3:02 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.5035 info
Change: -$0.4365 (-46%) info
Market Cap: $46.816M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets